Department Of Internal Medicine 4
151. Joint position statement from the Middle East and North Africa and sub-Saharan Africa on continuing to endorse the MAFLD definition
152. Joint position statement from the Middle East and North Africa and sub-Saharan Africa on continuing to endorse the MAFLD definition
153. Joint position statement from the Middle East and North Africa and sub-Saharan Africa on continuing to endorse the MAFLD definition
154. Short-term effect of ldl-apheresis on lipid profile of patients with nephrotic and non-nephrotic hyperlipidemia: A comparative study
155. Short-term effect of ldl-apheresis on lipid profile of patients with nephrotic and non-nephrotic hyperlipidemia: A comparative study
156. Urinary Protein Profiling for Potential Biomarkers of Chronic Kidney Disease: A Pilot Study
157. Still waters run deep: prognostic value of frequent premature ventricular complexes in seemingly normal hearts
158. Prevalence, years lived with disability, and trends in anaemia burden by severity and cause, 1990–2021: findings from the Global Burden of Disease Study 2021
159. Prevalence, years lived with disability, and trends in anaemia burden by severity and cause, 1990–2021: findings from the Global Burden of Disease Study 2021
160. Prevalence, years lived with disability, and trends in anaemia burden by severity and cause, 1990–2021: findings from the Global Burden of Disease Study 2021
161. Prevalence, years lived with disability, and trends in anaemia burden by severity and cause, 1990–2021: findings from the Global Burden of Disease Study 2021
162. Update on preclinical models of cancer therapy-related cardiac dysfunction: Challenges and perspectives. A scientific statement of the Heart Failure Association (HFA) of the ESC, the ESC Council of Cardio-Oncology, and the ESC Working Group on Cellular Biology of the Heart
163. Changes in body composition: the role of interleukins and adipokines (literature review)
164. Post-conflict acute stress reactions in Kazakhstan in the aftermath of January 2022 unrests: A national survey
165. Effects of air temperature on the number of ambulance calls for asthma during cold season in Nur-Sultan– the second coldest capital in the world
166. Trends and levels of the global, regional, and national burden of appendicitis between 1990 and 2021: findings from the Global Burden of Disease Study 2021
167. Burden of 375 diseases and injuries, risk-attributable burden of 88 risk factors, and healthy life expectancy in 204 countries and territories, including 660 subnational locations, 1990–2023: a systematic analysis for the Global Burden of Disease Study 2023
168. Burden of 375 diseases and injuries, risk-attributable burden of 88 risk factors, and healthy life expectancy in 204 countries and territories, including 660 subnational locations, 1990–2023: a systematic analysis for the Global Burden of Disease Study 2023
169. Burden of 375 diseases and injuries, risk-attributable burden of 88 risk factors, and healthy life expectancy in 204 countries and territories, including 660 subnational locations, 1990–2023: a systematic analysis for the Global Burden of Disease Study 2023
170. Burden of 375 diseases and injuries, risk-attributable burden of 88 risk factors, and healthy life expectancy in 204 countries and territories, including 660 subnational locations, 1990–2023: a systematic analysis for the Global Burden of Disease Study 2023
171. Burden of 375 diseases and injuries, risk-attributable burden of 88 risk factors, and healthy life expectancy in 204 countries and territories, including 660 subnational locations, 1990–2023: a systematic analysis for the Global Burden of Disease Study 2023
172. Global evolution of inflammatory bowel disease across epidemiologic stages
173. The global, regional, and national burden attributable to low bone mineral density, 1990–2020: an analysis of a modifiable risk factor from the Global Burden of Disease Study 2021
174. The global, regional, and national burden attributable to low bone mineral density, 1990–2020: an analysis of a modifiable risk factor from the Global Burden of Disease Study 2021
175. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension
176. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension
177. Assessing Fibrosis Progression and Endothelial Dysfunction in SSc-ILD and COPD: An Integrated Biomarker and CT Densitometry Approach
178. Features of Heart Failure with Preserved Ejection Fraction in Patients with Chronic Obstructive Pulmonary Disease and Systemic Sclerosis-Associated Interstitial Lung Diseases
179. Pulmo–Cardio–Renal Continuum in Chronic Lung Diseases: A 3-Year Prospective Cohort Study
180. Correction: Genistein as a regulator of signaling pathways and microRNAs in different types of cancers (Cancer Cell International, (2021), 21, 1, (388), 10.1186/s12935-021-02091-8)
181. Genistein as a regulator of signaling pathways and microRNAs in different types of cancers
182. Burden of chronic respiratory disease in Asia, 1990–2023: a systematic analysis for the Global Burden of Disease Study 2023
183. Burden of chronic respiratory disease in Asia, 1990–2023: a systematic analysis for the Global Burden of Disease Study 2023
184. Burden of chronic respiratory disease in Asia, 1990–2023: a systematic analysis for the Global Burden of Disease Study 2023
185. Genetic Determinants of Coronary Artery Disease in Type 2 Diabetes Mellitus Among Asian Populations: A Meta-Analysis
186. Prevention of Postoperative Urethral Strictures by Irrigation with 5-Fluorouracil via a Modified Urinary Catheter
187. CUBN GENE POLYMORPHISMS AND SUSCEPTIBILITY TO TYPE 2 DIABETES VERSUS TYPE 1 DIABETES: A SYSTEMATIC REVIEW
188. Access to prediabetes care: A SAFES statement
189. Access to prediabetes care: A SAFES statement
190. A second update on mapping the human genetic architecture of COVID-19
191. A second update on mapping the human genetic architecture of COVID-19
192. Global burden of amphetamine, cannabis, cocaine and opioid use in 204 countries, 1990–2023: a Global Burden of Disease Study
193. Global burden of amphetamine, cannabis, cocaine and opioid use in 204 countries, 1990–2023: a Global Burden of Disease Study
194. Global burden of amphetamine, cannabis, cocaine and opioid use in 204 countries, 1990–2023: a Global Burden of Disease Study
195. Global burden of amphetamine, cannabis, cocaine and opioid use in 204 countries, 1990–2023: a Global Burden of Disease Study
196. Global burden of amphetamine, cannabis, cocaine and opioid use in 204 countries, 1990–2023: a Global Burden of Disease Study
197. Global burden of amphetamine, cannabis, cocaine and opioid use in 204 countries, 1990–2023: a Global Burden of Disease Study
198. Global burden of amphetamine, cannabis, cocaine and opioid use in 204 countries, 1990–2023: a Global Burden of Disease Study
199. The prevalence of signs of thyroid pathology among students of the karaganda medical university according to the survey
200. Cardiovascular Disease Burden in Rural Central Asia: A Systematic Review of Epidemiological Trends and Mortality Patterns
1 2 3 4 5 6 10